Cargando…

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia

Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted covera...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Antoní, Kuraieva, Alona, Stone, Gregory G., Cillóniz, Catia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582922/
https://www.ncbi.nlm.nih.gov/pubmed/37852658
http://dx.doi.org/10.1183/16000617.0117-2023
_version_ 1785122444766347264
author Torres, Antoní
Kuraieva, Alona
Stone, Gregory G.
Cillóniz, Catia
author_facet Torres, Antoní
Kuraieva, Alona
Stone, Gregory G.
Cillóniz, Catia
author_sort Torres, Antoní
collection PubMed
description Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted coverage of suspected MRSA in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), are vancomycin and linezolid. However, adverse events such as acute kidney injury and Clostridium difficile infection have been associated with these antibiotics. Ceftaroline fosamil is a β-lactam/extended-spectrum cephalosporin approved for the treatment of adults and children with CAP and complicated skin and soft tissue infections. Ceftaroline has in vitro activity against a range of common Gram-positive bacteria and is distinct among the β-lactams in retaining activity against MRSA. Due to the design of the pivotal randomised controlled trials of ceftaroline fosamil, outcomes in patients with MRSA CAP were not evaluated. However, various reports of real-world outcomes with ceftaroline fosamil for pneumonia caused by MRSA, including CAP and HAP/VAP, been published since its approval. A systematic literature review and qualitative analysis of relevant publications was undertaken to collate and summarise relevant published data on the efficacy and safety of ceftaroline fosamil in patients with MRSA pneumonia. While relatively few real-world outcomes studies are available, the available data suggest that ceftaroline fosamil is a possible alternative to linezolid and vancomycin for MRSA pneumonia. Specific scenarios in which ceftaroline fosamil might be considered include bacteraemia and complicating factors such as empyema.
format Online
Article
Text
id pubmed-10582922
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-105829222023-10-19 Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia Torres, Antoní Kuraieva, Alona Stone, Gregory G. Cillóniz, Catia Eur Respir Rev Reviews Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted coverage of suspected MRSA in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), are vancomycin and linezolid. However, adverse events such as acute kidney injury and Clostridium difficile infection have been associated with these antibiotics. Ceftaroline fosamil is a β-lactam/extended-spectrum cephalosporin approved for the treatment of adults and children with CAP and complicated skin and soft tissue infections. Ceftaroline has in vitro activity against a range of common Gram-positive bacteria and is distinct among the β-lactams in retaining activity against MRSA. Due to the design of the pivotal randomised controlled trials of ceftaroline fosamil, outcomes in patients with MRSA CAP were not evaluated. However, various reports of real-world outcomes with ceftaroline fosamil for pneumonia caused by MRSA, including CAP and HAP/VAP, been published since its approval. A systematic literature review and qualitative analysis of relevant publications was undertaken to collate and summarise relevant published data on the efficacy and safety of ceftaroline fosamil in patients with MRSA pneumonia. While relatively few real-world outcomes studies are available, the available data suggest that ceftaroline fosamil is a possible alternative to linezolid and vancomycin for MRSA pneumonia. Specific scenarios in which ceftaroline fosamil might be considered include bacteraemia and complicating factors such as empyema. European Respiratory Society 2023-10-18 /pmc/articles/PMC10582922/ /pubmed/37852658 http://dx.doi.org/10.1183/16000617.0117-2023 Text en Copyright ©The authors 2023 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Reviews
Torres, Antoní
Kuraieva, Alona
Stone, Gregory G.
Cillóniz, Catia
Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
title Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
title_full Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
title_fullStr Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
title_full_unstemmed Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
title_short Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
title_sort systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant staphylococcus aureus pneumonia
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582922/
https://www.ncbi.nlm.nih.gov/pubmed/37852658
http://dx.doi.org/10.1183/16000617.0117-2023
work_keys_str_mv AT torresantoni systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia
AT kuraievaalona systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia
AT stonegregoryg systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia
AT cillonizcatia systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia